VivoSeq
Other

Levodopa

0

Pipeline Programs↗

0

Active Trials↗

8

Companies Involved↗

Levodopa is an early-stage landscape with 0 programs across 8 companies. The most active players are Novartis, Acorda Therapeutics, Shanghai WD Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalA

Acorda Therapeutics

0 programs

PreclinicalS

Shanghai WD Pharmaceutical Co., Ltd.

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalOrion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

40

clinical trials

Completed35 · 88%
Unknown status3 · 8%
Withdrawn2 · 5%

Clinical Trials

Trial Activity

40 trials

Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers
Completed·UUniversity of Buenos Aires·Phase 4·NCT01327261·24 enrolled
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
Completed·Novartis logoNovartis·Phase 1·NCT00415740·42 enrolled
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
Completed·Novartis logoNovartis·Phase 1·NCT00415922·42 enrolled
Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration
Completed·Roche logoRoche·Phase 1·NCT02116465·12 enrolled
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
Completed·BBial - Portela C S.A.·Phase 1·NCT03097211·38 enrolled
Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics
Completed·BBial - Portela C S.A.·Phase 1·NCT03091868·80 enrolled
Effect of Levodopa on Human Multifocal Electroretinogram
Completed·MMedical University of Vienna·Phase 4·NCT00812760·20 enrolled
Pharmacokinetic of Levodopa Study in Healthy Males
Completed·Orion Corporation, Orion Pharma logoOrion Corporation, Orion Pharma·Phase 1·NCT03140956·20 enrolled
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
Completed·BBial - Portela C S.A.·Phase 1·NCT01519284·82 enrolled
Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
Completed·AAcorda Therapeutics·Phase 1·NCT03887884·23 enrolled
Famotidine for Levodopa-induced Dyskinesia in PD
Completed·UUniversity Health Network, Toronto·Phase 2·NCT01937078·7 enrolled
A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT00460954·20 enrolled
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
Completed·NNeuroDerm Ltd.·Phase 1·NCT01486628·36 enrolled
A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
Completed·AAcorda Therapeutics·Phase 1·NCT02812394·24 enrolled
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Completed·BBial - Portela C S.A.·Phase 1·NCT01533116·52 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)